Adiponectin signaling in the liver

Reviews in Endocrine and Metabolic Disorders

Volumn 15, Issue 2, 2014, Pages 137-147

  Combs, Terry P ^a,b   Marliss, Errol B ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adiponectin; Amino acids; Autophagy; Blood glucose; Diabetes; Fatty acids; Glucose production; Insulin; Liver; SOGA

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CADHERIN; CERAMIDASE; GLUCOSE; ADIPONECTIN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AUTOPHAGY; CARDIOVASCULAR DISEASE; CELL SURFACE; ENZYME ACTIVITY; ENZYME REPRESSION; ENZYME SUBSTRATE; GLUCONEOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFE EXPECTANCY; LIPOTOXICITY; LIVER; LIVER CELL; LIVER DISEASE; METABOLIC BALANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; HUMAN; METABOLISM; NONALCOHOLIC FATTY LIVER; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPONECTIN; AMP-ACTIVATED PROTEIN KINASES; AUTOPHAGY; CADHERINS; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, ADIPONECTIN; SIGNAL TRANSDUCTION;

EID: 84901457990     PISSN: 13899155     EISSN: 15732606     Source Type: Journal    
DOI: 10.1007/s11154-013-9280-6     Document Type: Review

References (95)

1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746-9.
2. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18):10697-703.
3. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocytederived bioactive substances. Ann N YAcad Sci. 1999;892:146-54.
4. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002;13(2):84-9.
5. Haugen F, Drevon CA. Activation of nuclear factor kappaB by high molecular weight and globular adiponectin. Endocrinol. 2007;148(11):5478-86.
6. Schraw T, Wang ZV, Halberg N, Hawkins M, Scherer PE. Plasma adiponectin complexes have distinct biochemical characteristics. Endocrinol. 2008;149(5):2270-82.
7. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98(4):2005-10.
8. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem. 2003;278(11):9073-85.
9. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7(8):947-53.
10. Katz EB, Stenbit AE, Hatton K, DePinho R, Cahrron MJ. Cardiac and adipose tissue abnormalilties but not diabetes in mice deficient in GLUT4. Nature. 1995;377:151-5.
11. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Investig. 2001;108(12):1875-81.
12. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology. 2004;145(1):367-83.
13. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2006;281(5):2654-60.
14. Holland WL, Miller RA, Wang ZV, Sun K, Barth BM, Bui HH, et al. Receptor-mediated activation of ceramidase activity inititates the pleiotropic actions of adiponectin. Nat Med. 2011;17(1):55-65.
15. Wang Y, Xu A, Knight C, Xu LY, Cooper GJ. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem. 2002;277(22):19521-9.
16. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83.
17. Mynarcick DC, Combs TP, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. JAIDS. 2002;31(5):506-13.
18. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology. 2002;143(3):998-1007.
19. Brooks NL, Moore KS, Clark RD, Perfetti MT, Trent CM, Combs TP. Do low levels of circulating adiponectin represent a biomarker or just another risk factor for the metabolic syndrome? Diabetes Obes Metab. 2007;9(3):246-58.
20. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARgamma signaling and metabolism: the good the bad and the future. Nat Med. 2013;99:557-66.
21. Hoffstedt J, Arvidsson E, Sjolin E,WahlenK, Arner P. Adipose tissue adiponectin production and adiponectin seum concentration in human obesity and insulin resistance. J Clin Endocrinol Metab. 2004;89(3):1391-6.
22. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci. 2004;101(28):10308-13.
23. Chan CY, Lee JM, Chan PC, Ng IO. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. Cancer Cell Biol. 2008;123(5):1043-52.
24. Vestal DJ, Ranscht B. Glycosyl phosphatidylinositol-anchored T-cadherin mediates calcium-dependent, homophilic cell adhesion. J Cell Biol. 1992;119(2):451-61.
25. Denzel MS, Scimia M, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest. 2010;120(12):4342-52.
26. Philippova MP, Bochkov VN, Stambolsky DV, Tkachuk VA, Resink TJ. T-cadherin and signal-transducing moleculaes co-localize in caveolin-rich membrane domains of vascular smooth muscle cells. FEBS Lett. 1998;429:207-10.
27. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423(6941):762-9.
28. Mao X, Kikani CK, Riojas RA, Langlais P, Wang L, Ramos FJ, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol. 2006;8(5):516-23.
29. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-95.
30. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol/Eur Fed Endocr Soc. 2005;152(1):113-8.
31. Qiao L, Zou C, van der Westhuyzen DR, Shao J. Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism. Diabetes. 2008;57(7):1824-33.
32. Brooks NL, Trent CM, Raetzsch CF, Flurkey K, Boysen G, Perfetti MT, et al. Low utilization of circulating glucose after food withdrawal in Snell dwarf mice. J Biol Chem. 2007;282(48):35069-77.
33. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007;100(3):328-41.
34. Deepa SS, Dong LQ. APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab. 2009;296(1):E22-36.
35. Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, et al. Yin-Yang regulation of adiponectin signaling by APPL isoforms in muscle cells. J Biol Chem. 2009;284(46):31608-15.
36. Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol. 2000;20(18):6704-11.
37. Hattori Y, Nakano Y, Hattori S, Tomizawa A, Inukai K, Kasai K. High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells. FEBS Lett. 2008;582(12):1719-24.
38. Zhou L, Deepa SS, Etzler JC, Ryu J, Mao X, Fang Q, et al. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem. 2009;284(33):22426-35.
39. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature. 2010;464(7293):1313-9.
40. Buechler C, Wanninger J, Neumeier M. Adiponectin receptor binding proteins-recent advances in elucidating adiponectin signalling pathways. FEBS Lett. 2010;584(20):4280-6.
41. Viollet B, Andreelli F. AMP-activated protein kinase and metabolic control. Handb Exp Pharmacol. 2011;203:303-30.
42. Powell DJ, Hajduch E, Kular G, Hundal HS. Ceramide disables 3- phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol. 2003;23(21):7794-808.
43. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 2009;23(3):751-63.
44. Bourbon NA, Yun J, Berkey D, Wang Y, Kester M. Inhibitory actions of ceramide upon PKC-epsilon/ERK interactions. Am J Physiol Cell Physiol. 2001;280(6):C1403-11.
45. Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60(2):181-95.
46. Yang G, Badeanlou L, Bielawski J, Roberts AJ, Hannun YA, Samad F. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab. 2009;297(1):E211-24.
47. Yew NS, Zhao H, Hong EG, Wu IH, Przybylska M, Siegel C, et al. Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One. 2010;5(6):e11239.
48. Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, et al. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest. 2011;121(5):1858-70.
49. Lopez X, Goldfine AB, Holland WL, Gordillo R, Scherer PE. Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. J Pediatr Endocrinol Metab. 2013;24.
50. Villa NY, Kupchak BR, Garitaonandia I, Smith JL, Alonso E, Alford C, et al. Sphingolipids function as downstream effectors of a fungal PAQR. Mol Pharmacol. 2009;75(4):866-75.
51. Holland WL, Summers SA. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev. 2008;29(4):381-402.
52. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev. 2012;33(4):547-94.
53. Miller RA, Chu Q, Le Lay J, Scherer PE, Ahima RS, Kaestner KH, et al. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Investig. 2011;121(6):2518-28.
54. Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V, et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci U S A. 2003;100(24):14217-22.
55. Ma Y, Liu D. Hydrodynamic delivery of adiponectin and adiponectin receptor 2 gene blocks high-fat diet-induced obesity and insulin resistance. Gene Ther. 2013.
56. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology. 2006;147(5):2432-41.
57. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature. 2001;413(6852):131-8.
58. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642-6.
59. Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005;437(7062):1109-11.
60. Berasi SP, Huard C, Li D, Shih HH, Sun Y, Zhong W, et al. Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. J Biol Chem. 2006;281(37):27167-77.
61. Jorgensen SB, Nielsen JN, Birk JB, Olsen GS, Viollet B, Andreelli F, et al. The alpha2-5′AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes. 2004;53(12):3074-81.
62. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE. 5′-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J Biol Chem. 2001;276(50):46912-6.
63. Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab. 2011;13(4):401-12.
64. Dickens M, Svitek CA, Culbert AA, O'Brien RM, Tavare JM. Central role for phosphatidylinositide 3-kinase in the repression of glucose-6-phosphatase gene transcription by insulin. J Biol Chem. 1998;273(32):20144-9.
65. Nakae J, Kitamura T, Silver DL, Accili D. The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest. 2001;108(9):1359-67.
66. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science. 2003;300(5625):1574-7.
67. Oberkofler H, Pfeifenberger A, Soyal S, Felder T, Hahne P, Miller K, et al. Aberrant hepatic TRIB3 gene expression in insulin-resistant obese humans. Diabetologia. 2010;53(9):1971-5.
68. Cheng KK, Iglesias MA, Lam KS, Wang Y, Sweeney G, Zhu W, et al. APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice. Cell Metab. 2009;9(5):417-27.
69. Horton RA, Ceppi ED, Knowles RG, Titheradge MA. Inhibition of hepatic gluconeogenesis by nitric oxide: a comparison with endotoxic shock. Biochem J. 1994;299(Pt 3):735-9.
70. Wang Y, Cheng KK, Lam KS, Wu D, Wang Y, Huang Y, et al. APPL1 counteracts obesity-induced vascular insulin resistance and endothelial dysfunction by modulating the endothelial production of nitric oxide and endothelin-1 in mice. Diabetes. 2011;60(11):3044-54.
71. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem. 2002;277(33):29359- 62.
72. Geller DA, Nussler AK, Di Silvio M, Lowenstein CJ, Shapiro RA, Wang SC, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A. 1993;90(2):522-6.
73. Waltner-Law M, Daniels MC, Sutherland C, Granner DK. NF-kappa B inhibits glucocorticoid and cAMP-mediated expression of the phosphoenolpyruvate carboxykinase gene. J Biol Chem. 2000;275(41):31847-56.
74. Grempler R, Kienitz A, Werner T, Meyer M, Barthel A, Ailett F, et al. Tumour necrosis factor alpha decreases glucose-6-phosphatase gene expression by activation of nuclear factor kappaB. Biochem J. 2004;382(Pt 2):471-9.
75. Raetzsch CF, Brooks NL, Alderman JM, Moore KS, Hosick PA, Klebanov S, et al. Lipopolysaccharide inhibition of glucose production through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor kappa b pathway. Hepatology. 2009;50(2):592-600.
76. Thakur V, Pritchard MT, McMullen MR, Nagy LE. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G998-G1007.
77. Mittelman SD, Bergman RN. Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab. 2000;279(3):E630-7.
78. Felig P, Pozefsky T, Marliss E, Cahill Jr GF. Alanine: key role in gluconeogenesis. Science. 1970;167(3920):1003-4.
79. Felig P, Marliss E, Owen OE, Cahill Jr GF. Role of substrate in the regulation of hepatic gluconeogenesis in fasting man. Adv Enzyme Regul. 1969;7:41-6.
80. Molusky MM, Li S, Ma D, Yu L, Lin JD. Ubiquitin-specific protease 2 regulates hepatic gluconeogenesis and diurnal glucose metabolism through 11beta-hydroxysteroid dehydrogenase 1. Diabetes. 2012;61(5):1025-35.
81. Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37(6):1136-42.
82. Mortimore GE, Hutson NJ, Surmacz CA. Quantitative correlation between proteolysis and macro- and microautophagy in mouse hepatocytes during starvation and refeeding. Proc Natl Acad Sci U S A. 1983;80(8):2179-83.
83. Amherdt M, Harris V, Renold AE, Orci L, Unger RH. Hepatic autography in uncontrolled experimental diabetes and its relationships to insulin and glucagon. J Clin Investig. 1974;54(1):188-93.
84. Shelburne JD, Arstila AU, Trump BF. Studies on cellular autophagocytosis. Cyclic AMP- and dibutyryl cyclic AMPstimulated autophagy in rat liver. Am J Pathol. 1973;72(3):521-40.
85. Lenk SE, Bhat D, Blakeney W, Dunn Jr WA. Effects of streptozotocin- induced diabetes on rough endoplasmic reticulum and lysosomes of rat liver. Am J Physiol. 1992;263(5 Pt 1):E856-62.
86. Forbes JM. The physiological deadlock between AMPK and gluconeogenesis: SOGA, a novel protein, may provide the key. Am J Pathol. 2010;177(4):1600-2.
87. Zhao M, Klionsky DJ. AMPK-dependent phosphorylation of ULK1 induces autophagy. Cell Metab. 2011;13(2):119-20.
88. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17(6):596-603.
89. Cowherd RB, Asmar MM, Alderman JM, Alderman EA, Garland AL, Busby WH, et al. Adiponectin lowers glucose production by increasing SOGA. Am J Pathol. 2010;177(4):1936-45.
90. Longnus SL, Wambolt RB, Parsons HL, Brownsey RW, Allard MF. 5-Aminoimidazole-4-carboxamide 1-beta -D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. Am J Physiol Regul Integr Comp Physiol. 2003;284(4):R936-44.
91. Camacho RC, Pencek RR, Lacy DB, James FD, Donahue EP, Wasserman DH. Portal venous 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion overcomes hyperinsulinemic suppression of endogenous glucose output. Diabetes. 2005;54(2):373-82.
92. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J. 2007;404(1):15-21.
93. Gougeon R, Morais JA, Chevalier S, Pereira S, Lamarche M, Marliss EB. Determinants of whole-body protein metabolism in subjects with and without type 2 diabetes. Diabetes Care. 2008;31(1):128-33.
94. Gougeon R, Pencharz PB, Marliss EB. Effect of NIDDM on the kinetics of whole-body protein metabolism. Diabetes. 1994;43(2):318-28.
95. Imagawa A, Funahashi T, Nakamura T, Moriwaki M, Tanaka S, Nishizawa H, et al. Elevated serum concentration of adiposederived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care. 2002;25(9):1665-6.